Table 4.
Frequency of the RAD51 haplotypes among endometrial cancer patients and control subjects
| Haplotypes RAD51-135–172 | Patients (n = 630) N (%) | Controls (n = 630) N (%) | OR (95 % CI)a | p b |
|---|---|---|---|---|
| G/G–G/G | 45 (7.1) | 75 (11.9) | 1.00 Ref. | |
| G/G–G/T | 48 (7.6) | 51 (8.1) | 1.56 (0.91–2.69) | 0.134 |
| G/G–T/T | 45 (7.1) | 60 (9.5) | 1.25 (0.73–2.13) | 0.492 |
| G/C–G/G | 20 (8.1) | 72 (11.7) | 0.46 (0.24–0.85) | 0.020 |
| G/C–G/T | 45 (7.1) | 114 (11.4) | 0.66 (0.39–1.09) | 0.134 |
| G/C–T/T | 45 (7.1) | 75 (11.9) | 1.00 (0.59–1.68) | 0.887 |
| C/C–G/G | 120 (14.3) | 57 (9.0) | 3.50 (2.15–5.70) | <0.0001 |
| C/C–G/T | 165 (26.2) | 69 (10.9) | 3.98 (2.50–6.34) | <0.0001 |
| C/C–T/T | 96 (15.2) | 57 (9.0) | 2.81 (1.71–4.60) | <0.0001 |
Data in boldface are statistically significant
aCrude odds ratio (OR); 95 % CI, confidence interval at 95 %
bChi-square